Compare VRME & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | SNSE |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 10.3M |
| IPO Year | N/A | 2021 |
| Metric | VRME | SNSE |
|---|---|---|
| Price | $0.63 | $8.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.50 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 443.8K | 81.6K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $5.00 |
| 52 Week High | $5.00 | $18.35 |
| Indicator | VRME | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 50.35 |
| Support Level | $0.65 | $8.50 |
| Resistance Level | $0.67 | $9.60 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 4.40 | 70.44 |
VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).